Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Incyte (INCY) PT Raised to $98 at Mizuho Securities
October 30, 2019 8:03 AM EDTMizuho Securities analyst Mara Goldstein raised the price target on Incyte (NASDAQ: INCY) to $98.00 (from $95.00) while maintaining a Buy rating.
The analyst commented, "We continue to like INCY based on the combination of cash flow generated by JAKAFI and opportunities from potential... More
Incyte (INCY) Tops Q3 EPS by 17c, Revenues Beat; Raises FY19 Jakafi Revenue Outlook
October 29, 2019 7:12 AM EDTIncyte (NASDAQ: INCY) reported Q3 EPS of $0.82, $0.17 better than the analyst estimate of $0.65. Revenue for the quarter came in at $551.58 million versus the consensus estimate of $534.88 million.
Total product and royalty revenues of $534 million (+24% vs. Q3 2018) and Jakafi® (ruxolitinib) revenues of $433 million (+25% vs. Q3 2018) for the quarter ended September 30, 2019;... More